Company profile: OncoMed
1.1 - Company Overview
Company description
- Provider of biotechnology therapeutics developing monoclonal antibodies that target pathways critical to tumor-initiating (cancer stem) cells to improve cancer treatment. Pipeline includes etigilimab with nivolumab for advanced solid tumors, navicixizumab for platinum-resistant ovarian cancer (with OncXerna), setrusumab for OI, alvelestat for AATD-LD, acumapimod for AECOPD, and leflutrozole (with ReproNovo).
Products and services
- Etigilimab: An investigational monoclonal antibody studied in combination with nivolumab for advanced or metastatic solid tumors, showing promising efficacy in certain cancer types
- Navicixizumab: An oncology drug for platinum-resistant ovarian cancer, partnered with OncXerna Therapeutics Inc. for further development, addressing treatment in the resistant disease
- Leflutrozole: A novel once-weekly oral aromatase inhibitor partnered with ReproNovo for further development, offering once-weekly oral dosing as its defining administration schedule
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to OncoMed
Celleron Therapeutics
HQ: United Kingdom
Website
- Description: Provider of oncology therapeutics and biomarker-driven precision medicine, developing epigenetic biomarkers to match drugs to responsive disease. Pipeline includes Zabadinostat, an immune modulator with clinical activity in colorectal cancer, liver cancer, and lymphoma; PCV-001, a preclinical precision cancer vaccine; and AT-101, an in-house PRMT5 inhibitor in clinical planning.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Celleron Therapeutics company profile →
Arius Research
HQ: Canada
Website
- Description: Provider of biotechnology solutions centered on the discovery and development of antibody therapeutics, primarily targeting breast, prostate, ovarian, colorectal, pancreatic and lung cancers, leukemia, and melanoma, leveraging its FunctionFIRST platform to identify monoclonal antibodies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arius Research company profile →
Lava Therapeutics
HQ: The Netherlands
Website
- Description: Provider of a bispecific antibody platform engaging gamma-delta (Vγ9Vδ2) T cells for treatment of hematological and solid cancers. Offers the Gammabody® platform to generate T cell engagers targeting tumor-associated antigens, and drug candidates LAVA-051 for hematologic malignancies and solid tumors, and LAVA-1207 for metastatic castration-resistant prostate cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lava Therapeutics company profile →
Bellwether Bio
HQ: United States
Website
- Description: Provider of novel cell-free DNA-based diagnostic technologies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bellwether Bio company profile →
Immune-Onc Therapeutics
HQ: United States
Website
- Description: Provider of therapeutic antibodies for cancer treatment, developing IO-202, a humanized IgG1 targeting LILRB4 to deplete LILRB4-expressing cells in blood cancers, autoimmune, and inflammatory diseases; IO-108, a fully human IgG4 targeting LILRB2 to block cancer-associated immune suppression in solid tumors; and IO-312, a bispecific targeting LILRB4 and CD3 for AML and other hematologic malignancies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immune-Onc Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for OncoMed
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to OncoMed
2.2 - Growth funds investing in similar companies to OncoMed
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for OncoMed
4.2 - Public trading comparable groups for OncoMed
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →